chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19
Symptoms: Atrial fibrillation, Cognitive disorder, Heart rate, Heart rate increased, Hyperhidrosis
Clinical narrative: Heart beats per minute go up to a 177 / Bounced my heart beat per minute very high; A. Fib. Symptoms; Having a real hard time understanding; I had sweats; This is a spontaneous report from a contactable consumer (patient). A 87-year-old patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Batch/Lot number was not reported), via an unspecified route of administration on 06Oct2021 as dose 3, single for COVID-19 immunisation. The patient's medical history and the concomitant medications were not reported. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Batch/Lot number was not reported), via an unspecified route of administration on an unknown date as dose 1, single for COVID-19 immunisation and received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Batch/Lot number was not reported), via an unspecified route of administration on an unknown date as dose 2, single for COVID-19 immunisation. On an unknown date in Oct2021, the patient's heart beats per minute go up to a 177 and had sweats and with this AFib (atrial fibrillation) symptoms. In Oct2021, the patient had not had other symptoms like left arm pain or chest heaviness, but it had bounced the patient's heartbeat per minute, very high. It was really doing a number on patient's heart beats per minute. The patient couldn't understand and had a real hard time understanding. The patient underwent lab tests and procedures which included heart rate: 177 in Oct2021, heart rate: high on Oct2021 and bounced heartbeat per minute very high. The outcome was unknown for the reported events.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report from a contactable consumer (patient) via a Pfizer-sponsored program. A 71-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on 05Mar2021 (Batch/Lot number was not reported) as dose 1, single, then via an unspecified route of administration on 26Mar2021 (Batch/Lot number was not reported) as dose 2, single for covid-19 immunisation (vaccinated at age 71-year-old). There was no medical history. Patient's son passed away from COVID-19. There were no concomitant medication and no other vaccine received within four weeks. Patient had covid 19 on 23Aug2021 which resulted in physician office visit. She did not get sick, she only had a cough. She didn't lose taste or all these other things they were talking about happening. She wanted to know if it is too soon to get the booster; she was scheduled for the booster dose on Tuesday (unspecified date). Her isolation was over in Sept2021. The patient underwent lab tests and procedures which included Covid 19 Test: positive on 23Aug2021. Outcome of the events was recovered on Sep2021.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood pressure measurement, Heart rate, Heart rate increased, Hypertensive crisis, SARS-CoV-2 test
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Activated partial thromboplastin time normal, Adverse reaction, Angiogram, Antinuclear antibody negative, Blood catecholamines
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood homocysteine normal, Blood pressure increased, Blood test normal, Borrelia test negative, Burning sensation
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: C-reactive protein normal, Computerised tomogram abdomen normal, Computerised tomogram head normal, Computerised tomogram normal, Computerised tomogram thorax normal
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Dysphemia, Echocardiogram, Electric shock sensation, Electrocardiogram normal
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fibrin D dimer increased, Full blood count normal, Gait disturbance, Head discomfort, Hypertensive emergency
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Liver function test normal, Loss of personal independence in daily activities, Magnetic resonance imaging head normal
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Magnetic resonance imaging neck, Malaise, Metabolic function test, Metabolic function test normal, Palpitations
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Paraesthesia, Photopsia, Red blood cell sedimentation rate normal, Tachycardia, Tinnitus
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tremor, Ultrasound Doppler normal, Ultrasound scan normal, Venogram normal
Clinical narrative: I went into a hypertensive crisis 2 days after receiving the first dose / my blood pressure was 243/167; Also, my heart rate was elevates=d. I spent 4; This is a spontaneous report from a contactable other health professional (patient).  A 45-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: FC3182), via an unspecified route of administration, administered in arm right on 01Oct2021 at 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunisation. Medical history included known allergies: Iodine contrast. Concomitant medication included omeprazole (PRILOSEC [OMEPRAZOLE]) taken for an unspecified indication, start and stop date were not reported. The patient went into a hypertensive crisis 2 days after receiving the first dose, on 03Oct2021 at 13:45. Her blood pressure was 243/167 on 03Oct2021 at 13:45, an ambulance had to come get her and give her nitro. Also, her heart rate was elevated on 03Oct2021 at 13:45. She spent 4 days in the hospital and was still having problems. The events resulted in emergency room/department or urgent care and hospitalization. The patient underwent lab tests and procedures which included blood pressure measurement: 243/167, heart rate: elevates on 03Oct2021, SARS-COV-2 test: negative (Nasal Swab) on 07Oct2021. Therapeutic measures were taken as a result of all events. The outcome of the events was not recovered.; Sender's Comments: Based on temporal association, the causal relationship between BNT162B2 and the event hypertensive crisis  and heart rate increased cannot be excluded. The information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asymptomatic COVID-19, Blood culture positive, Chest pain, Chills, Cough
Clinical narrative: Pt is a 58 y.o. male with a PMH of chronic lyme disease, HTN, atrial fibrillation and DVT on Eliquis, and metastatic high grade rectal NET with hepatic, mesenteric, and pelvic involvement s/p colostomy and pelvic wall resection currently on carboplatin/irinotecan presents to UK ED after being called for positive blood cultures.  Constitutional: Positive for chills and fever. Negative for fatigue and unexpected weight change.  Respiratory: Positive for cough. Negative for apnea, chest tightness, shortness of breath, wheezing and stridor.   Cardiovascular: Positive for chest pain. Negative for palpitations and leg swelling.   He tested positive for COVID-19 and was asymptomatic for COVID-19 other than the fever on his first ED visit 8/26 and didn't require any treatment.
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Pt is a 58 y.o. male with a PMH of chronic lyme disease, HTN, atrial fibrillation and DVT on Eliquis, and metastatic high grade rectal NET with hepatic, mesenteric, and pelvic involvement s/p colostomy and pelvic wall resection currently on carboplatin/irinotecan presents to UK ED after being called for positive blood cultures.  Constitutional: Positive for chills and fever. Negative for fatigue and unexpected weight change.  Respiratory: Positive for cough. Negative for apnea, chest tightness, shortness of breath, wheezing and stridor.   Cardiovascular: Positive for chest pain. Negative for palpitations and leg swelling.   He tested positive for COVID-19 and was asymptomatic for COVID-19 other than the fever on his first ED visit 8/26 and didn't require any treatment.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Injection site bruising, Injection site pain, Injection site swelling, Paraesthesia
Clinical narrative: Site: Bruising at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Numbness (specify: facial area, extremities)-Medium, Additional Details: Numbness/Tingling in hands and face the day after
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Error: Booster Given Too Early-
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: Site: Pain at Injection Site-Severe
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Fatigue, Lethargy, Nausea
Clinical narrative: Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Systemic: Fainting / Unresponsive-Mild, Systemic: Nausea-Medium, Systemic: Weakness-Medium, Additional Details: patient was given second shot and about 3 to 5 minutes later he passed out for less than a second and then reported dizziness and nausea. re was drinking some water and then passed out for less than a second a second time
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Syncope, Unresponsive to stimuli
Clinical narrative: Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Systemic: Fainting / Unresponsive-Mild, Systemic: Nausea-Medium, Systemic: Weakness-Medium, Additional Details: patient was given second shot and about 3 to 5 minutes later he passed out for less than a second and then reported dizziness and nausea. re was drinking some water and then passed out for less than a second a second time
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Abdominal pain upper, Arthralgia, Body temperature decreased, Chills, Decreased appetite
Clinical narrative: Immediately, when injected into upper left arm, extreme muscle pain, swelling and redness occurred. Within 15 minutes, ringing in ears, slight dizziness occurred. Within 35 minutes nausea, headache, severe stomach cramps, extreme pain in my knees, arm froze (could not move joints, could wiggle fingers), chills, dry mouth and drop in body temperature with shallow breathing at night. These symptoms persisted for the next 5 days with loss of appetite. From days 6-9, stomach was better, chills only at dinner time, and my arm unfroze gradually, finally reaching 100% mobility by 10/20/21. Itching at injection sit persisted until 10/21/21.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Dizziness, Dry mouth, Erythema, Headache, Hypoaesthesia
Clinical narrative: Immediately, when injected into upper left arm, extreme muscle pain, swelling and redness occurred. Within 15 minutes, ringing in ears, slight dizziness occurred. Within 35 minutes nausea, headache, severe stomach cramps, extreme pain in my knees, arm froze (could not move joints, could wiggle fingers), chills, dry mouth and drop in body temperature with shallow breathing at night. These symptoms persisted for the next 5 days with loss of appetite. From days 6-9, stomach was better, chills only at dinner time, and my arm unfroze gradually, finally reaching 100% mobility by 10/20/21. Itching at injection sit persisted until 10/21/21.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Hypopnoea, Immediate post-injection reaction, Injection site pruritus, Mobility decreased, Myalgia
Clinical narrative: Immediately, when injected into upper left arm, extreme muscle pain, swelling and redness occurred. Within 15 minutes, ringing in ears, slight dizziness occurred. Within 35 minutes nausea, headache, severe stomach cramps, extreme pain in my knees, arm froze (could not move joints, could wiggle fingers), chills, dry mouth and drop in body temperature with shallow breathing at night. These symptoms persisted for the next 5 days with loss of appetite. From days 6-9, stomach was better, chills only at dinner time, and my arm unfroze gradually, finally reaching 100% mobility by 10/20/21. Itching at injection sit persisted until 10/21/21.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Nausea, Swelling, Tinnitus
Clinical narrative: Immediately, when injected into upper left arm, extreme muscle pain, swelling and redness occurred. Within 15 minutes, ringing in ears, slight dizziness occurred. Within 35 minutes nausea, headache, severe stomach cramps, extreme pain in my knees, arm froze (could not move joints, could wiggle fingers), chills, dry mouth and drop in body temperature with shallow breathing at night. These symptoms persisted for the next 5 days with loss of appetite. From days 6-9, stomach was better, chills only at dinner time, and my arm unfroze gradually, finally reaching 100% mobility by 10/20/21. Itching at injection sit persisted until 10/21/21.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Admitted to Hospital on Date of Adverse Event [recorded in VAERS] for treatment of Covid-19 Positive following completion of Covid Vaccine Series.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Limb injury, Paraesthesia
Clinical narrative: Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)-
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Computerised tomogram, Deep vein thrombosis, Ultrasound Doppler
Clinical narrative: Developed a DVT related to the administration of the covid-19 vaccine or the ingredients of the vaccine
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Right Supraclavicular Lymphadenopathy
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Today is 10 days post my first vaccine injection. For the first 3 days, my arm was red, tender-to-the-touch, swollen and warm. After 3 days, those symptoms dissapated completely. This morning, I woke up with a red, raised bump that is tender-to-the-touch and warm. It feels like I just got another injection, but I did not.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Nasal congestion, Parosmia, Respiratory tract congestion, Taste disorder
Clinical narrative: Systemic: stuffy nose for 1 week then altered taste/smell-Mild, Additional Details: Patient reports a stuffy nose that last 1 week after the vaccine then had alterned taste and smell since the congestion resolved. He reports everything having a chemical smell or taste.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Lymphadenopathy, Neck pain
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Body Aches Generalized-Medium, Systemic: Lymph Node Swelling-Mild, Additional Details: Pt called pharmacy after experiencing pain and redness at injection site. Described a knot on her arm with some pain radiating up into neck. Will call back if not relieved by IBU or ice, or if noticable spreading of discoloration.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Nodule, Pain, Pain in extremity
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Body Aches Generalized-Medium, Systemic: Lymph Node Swelling-Mild, Additional Details: Pt called pharmacy after experiencing pain and redness at injection site. Described a knot on her arm with some pain radiating up into neck. Will call back if not relieved by IBU or ice, or if noticable spreading of discoloration.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Dyspnoea, Fatigue, Injection site pain, Pyrexia
Clinical narrative: Slight fever, pain around injection site in arm, fatigue,  tightness in chest, difficulty taking deep breaths,  throat partially closing.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Throat tightness
Clinical narrative: Slight fever, pain around injection site in arm, fatigue,  tightness in chest, difficulty taking deep breaths,  throat partially closing.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Wrong patient
Clinical narrative: Error: Wrong Patient (documentation in EMR)-
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Error: Wrong Dose of Vaccine - Too High.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Error: Wrong Dose of Vaccine - Too High-
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood test, Electrocardiogram, Gait disturbance, Groin pain
Clinical narrative: Heart palpitations begin within 24 hours and lasted about 24 hours aspirin was taken... Within 48 hours joint pain in my groin unable to walk normally and put pressure on my leg.  My provider gave an EKG it turned out normal on that following Tuesday she thought I pulled something but I only rested the day after the vaccine because of the heart palpitations...no exercise or nothing was done to pull anything...I am still having groin pain a week later.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Muscular weakness, Palpitations
Clinical narrative: Heart palpitations begin within 24 hours and lasted about 24 hours aspirin was taken... Within 48 hours joint pain in my groin unable to walk normally and put pressure on my leg.  My provider gave an EKG it turned out normal on that following Tuesday she thought I pulled something but I only rested the day after the vaccine because of the heart palpitations...no exercise or nothing was done to pull anything...I am still having groin pain a week later.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Condition aggravated, Headache, Heavy menstrual bleeding, Inappropriate schedule of product administration
Clinical narrative: Received first injection 09/21, had heavy cycle the next day and spotting for one week after. Had second injection on 10/21 and had chills, body aches, and headache. Started heavier than usual menstrual cycle the next day, bleeding through a pad every hour and a half, continued til today (2 days after injection).
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Received first injection 09/21, had heavy cycle the next day and spotting for one week after. Had second injection on 10/21 and had chills, body aches, and headache. Started heavier than usual menstrual cycle the next day, bleeding through a pad every hour and a half, continued til today (2 days after injection).
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: Error: Wrong Vaccine Formulation  (ex. different manufact. initial and booster)-
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue
Clinical narrative: Error: Incorrect Reconstitution-
Age: 52.0
Sex: F
Vaccine: FLU4
Symptoms: Back pain, Injection site pain, Lymphadenopathy, Ultrasound Doppler normal
Clinical narrative: soreness and pain at injection site that worsened in left arm upper back and left axilla lymphadenopathy
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue
Clinical narrative: Error: Incorrect Reconstitution-
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Condition aggravated, Ear discomfort, Extra dose administered
Clinical narrative: 1/ 2 booster dose.Strong Headache, throbbing eardrums, chills, vomiting (just once),sore arm,  weakness and body aches , no sleep, still feel lousy
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Headache, Insomnia, Pain, Pain in extremity
Clinical narrative: 1/ 2 booster dose.Strong Headache, throbbing eardrums, chills, vomiting (just once),sore arm,  weakness and body aches , no sleep, still feel lousy
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: 1/ 2 booster dose.Strong Headache, throbbing eardrums, chills, vomiting (just once),sore arm,  weakness and body aches , no sleep, still feel lousy
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue
Clinical narrative: Error: Incorrect Reconstitution-
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Error: Booster Given Too Early-
Age: 60.0
Sex: F
Vaccine: COVID19, FLUC4
Symptoms: Oedema peripheral
Clinical narrative: There is an enlarged area under left arm. Area of swelling is approximately 8 cm in diameter. I first noticed the enlargement at 3:00 pm 10/21/2021. This morning at 8:00 am on 10/22/2021 the area of swelling has gotten even larger. Pain down the left arm persists.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Aspergillus infection, Atrial fibrillation, Bronchial secretion retention, Bronchoscopy, COVID-19
Clinical narrative: Patient is a 68 y.o. female with PMHX of COPD, afib on eliquis, DM2, HTN, HLD, chronic anemia, HFpEF, OSA presented to ED on 8/5 with complaints of worsening SOA x4 days with associated fever, cough, dizziness.  Constitutional: Positive for diaphoresis, fatigue and fever.  HENT: Positive for congestion.   Respiratory: Positive for cough, chest tightness and shortness of breath.    Hospital Course: Upon admission, patient required escalating oxygen requirements and was admitted to the ICU. She was intubated on 9/8 due to worsening hypoxia. She was treated with 10 days of IV dex and an empiric course of antibiotics with 2 days of Vanc and 7 days of Cefepime. CT PE was obtained which showed no PE. Her course was complicated by mucus plugging on 9/10 requiring bronchoscopy. She was found to have aspergillus at that time and started on voriconazole for a 6week course. She was unable to be weaned from the vent and tracheostomy was performed on 9/27 by ENT.   She also experienced Afib RVR during her hospitalization which required beta-blockade, diltiazem gtt, and amiodarone.   On 10/1, she underwent bronchoscopy for BAL sample as concern for new VAP. That night, her O2 saturations decreased to the mid 80s sustaining. She also became hypotensive, requiring vasopressors.  Patient is DNR/DNI and passed away on 10/02
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Computerised tomogram thorax normal, Cough, Death, Dizziness
Clinical narrative: Patient is a 68 y.o. female with PMHX of COPD, afib on eliquis, DM2, HTN, HLD, chronic anemia, HFpEF, OSA presented to ED on 8/5 with complaints of worsening SOA x4 days with associated fever, cough, dizziness.  Constitutional: Positive for diaphoresis, fatigue and fever.  HENT: Positive for congestion.   Respiratory: Positive for cough, chest tightness and shortness of breath.    Hospital Course: Upon admission, patient required escalating oxygen requirements and was admitted to the ICU. She was intubated on 9/8 due to worsening hypoxia. She was treated with 10 days of IV dex and an empiric course of antibiotics with 2 days of Vanc and 7 days of Cefepime. CT PE was obtained which showed no PE. Her course was complicated by mucus plugging on 9/10 requiring bronchoscopy. She was found to have aspergillus at that time and started on voriconazole for a 6week course. She was unable to be weaned from the vent and tracheostomy was performed on 9/27 by ENT.   She also experienced Afib RVR during her hospitalization which required beta-blockade, diltiazem gtt, and amiodarone.   On 10/1, she underwent bronchoscopy for BAL sample as concern for new VAP. That night, her O2 saturations decreased to the mid 80s sustaining. She also became hypotensive, requiring vasopressors.  Patient is DNR/DNI and passed away on 10/02
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea, Endotracheal intubation, Fatigue, Hyperhidrosis, Hypotension
Clinical narrative: Patient is a 68 y.o. female with PMHX of COPD, afib on eliquis, DM2, HTN, HLD, chronic anemia, HFpEF, OSA presented to ED on 8/5 with complaints of worsening SOA x4 days with associated fever, cough, dizziness.  Constitutional: Positive for diaphoresis, fatigue and fever.  HENT: Positive for congestion.   Respiratory: Positive for cough, chest tightness and shortness of breath.    Hospital Course: Upon admission, patient required escalating oxygen requirements and was admitted to the ICU. She was intubated on 9/8 due to worsening hypoxia. She was treated with 10 days of IV dex and an empiric course of antibiotics with 2 days of Vanc and 7 days of Cefepime. CT PE was obtained which showed no PE. Her course was complicated by mucus plugging on 9/10 requiring bronchoscopy. She was found to have aspergillus at that time and started on voriconazole for a 6week course. She was unable to be weaned from the vent and tracheostomy was performed on 9/27 by ENT.   She also experienced Afib RVR during her hospitalization which required beta-blockade, diltiazem gtt, and amiodarone.   On 10/1, she underwent bronchoscopy for BAL sample as concern for new VAP. That night, her O2 saturations decreased to the mid 80s sustaining. She also became hypotensive, requiring vasopressors.  Patient is DNR/DNI and passed away on 10/02
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, Intensive care, Mechanical ventilation, Oxygen saturation decreased, Pyrexia
Clinical narrative: Patient is a 68 y.o. female with PMHX of COPD, afib on eliquis, DM2, HTN, HLD, chronic anemia, HFpEF, OSA presented to ED on 8/5 with complaints of worsening SOA x4 days with associated fever, cough, dizziness.  Constitutional: Positive for diaphoresis, fatigue and fever.  HENT: Positive for congestion.   Respiratory: Positive for cough, chest tightness and shortness of breath.    Hospital Course: Upon admission, patient required escalating oxygen requirements and was admitted to the ICU. She was intubated on 9/8 due to worsening hypoxia. She was treated with 10 days of IV dex and an empiric course of antibiotics with 2 days of Vanc and 7 days of Cefepime. CT PE was obtained which showed no PE. Her course was complicated by mucus plugging on 9/10 requiring bronchoscopy. She was found to have aspergillus at that time and started on voriconazole for a 6week course. She was unable to be weaned from the vent and tracheostomy was performed on 9/27 by ENT.   She also experienced Afib RVR during her hospitalization which required beta-blockade, diltiazem gtt, and amiodarone.   On 10/1, she underwent bronchoscopy for BAL sample as concern for new VAP. That night, her O2 saturations decreased to the mid 80s sustaining. She also became hypotensive, requiring vasopressors.  Patient is DNR/DNI and passed away on 10/02
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory tract congestion, SARS-CoV-2 test positive, Tracheostomy
Clinical narrative: Patient is a 68 y.o. female with PMHX of COPD, afib on eliquis, DM2, HTN, HLD, chronic anemia, HFpEF, OSA presented to ED on 8/5 with complaints of worsening SOA x4 days with associated fever, cough, dizziness.  Constitutional: Positive for diaphoresis, fatigue and fever.  HENT: Positive for congestion.   Respiratory: Positive for cough, chest tightness and shortness of breath.    Hospital Course: Upon admission, patient required escalating oxygen requirements and was admitted to the ICU. She was intubated on 9/8 due to worsening hypoxia. She was treated with 10 days of IV dex and an empiric course of antibiotics with 2 days of Vanc and 7 days of Cefepime. CT PE was obtained which showed no PE. Her course was complicated by mucus plugging on 9/10 requiring bronchoscopy. She was found to have aspergillus at that time and started on voriconazole for a 6week course. She was unable to be weaned from the vent and tracheostomy was performed on 9/27 by ENT.   She also experienced Afib RVR during her hospitalization which required beta-blockade, diltiazem gtt, and amiodarone.   On 10/1, she underwent bronchoscopy for BAL sample as concern for new VAP. That night, her O2 saturations decreased to the mid 80s sustaining. She also became hypotensive, requiring vasopressors.  Patient is DNR/DNI and passed away on 10/02